Skip to content

Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02309970
Enrollment
90
Registered
2014-12-05
Start date
2014-12-31
Completion date
2016-03-31
Last updated
2014-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Brief summary

CT perfusion (CTP) of the brain is an innovative technique to identify rapidly regions which are only partially or insufficiently perfused during an acute ischemic event. The differentiation between the core infarct and the still viable penumbra is its major clinical application. CTP helps directly in the decision-making process in the event of acute ischemic stroke by increasing the potential of success in patient who can benefit from thrombolytic/endovascular treatment. The use of CTP in patient selection for thrombolytic/endovascular treatment was never evaluated in a prospective randomized study. Yet, clinical experience well demonstrated a good correlation between the size of the penumbra and the clinical outcome when done in early as well as late stages of the event. The importance of identifying the penumbra in the acute phase of the ischemic stroke is widely accepted. But crucial evidence to support the predictive value of CTP to predict the clinical and anatomical/structural outcomes in the late phases (90 days after) is lacking. Currently, the use of CTP is based on theoretical assumptions and expert opinions but a randomized prospective study to validate its use is lacking. The current guidelines restrict the use of CTP trials and to patients that can't performed MRI scan.

Interventions

DRUGacetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran

subject in this group will receive oral treatment with anti platelet drug

DRUGalteplase

subject in this group will receive intravenous tPA

PROCEDUREendovascular

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* NIHSS\>=8 * up to 6 hours from event onset

Exclusion criteria

* mRS\>= 3 before the start of the event * life expectency \<1 year because other disability disease

Design outcomes

Primary

MeasureTime frame
The predictive value of CTP in identifying penumbra (salvagable brain tissue) in event of ischemic strokethree month

Countries

Israel

Contacts

Primary ContactGuy Raphaeli, MD
guyre@clalit.org.il972-50-4065626
Backup ContactOphir Keret, MD
ophirke@clalit.org.il972-3-9377080

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026